Small-molecule inhibitor technology for modulating DNA repair to treat repeat expansion disorders and cancers

Background

Nucleotide repeat expansion disorders represent a significant challenge in the field of genetics and neurology. These disorders, which include conditions such as Huntington’s disease, amyotrophic lateral sclerosis (ALS), and Friedreich ataxia, arise from the abnormal expansion of short tandem repeats—especially trinucleotide repeats—within the human genome. The expanded repeats disrupt normal gene function and lead to progressive neurological and systemic symptoms. The underlying molecular mechanisms often involve the formation of unusual DNA structures and errors in DNA repair pathways, particularly those mediated by the MSH3/MutSβ complex. Given the severity and prevalence of these disorders, and the lack of curative treatments, there is a pressing need for therapies that directly address the root causes of repeat expansion and its pathological consequences.

Current approaches to treating nucleotide repeat expansion disorders are largely symptomatic, focusing on managing disease manifestations rather than halting or reversing the underlying genetic instability. Existing therapies do not effectively target the DNA repair pathways responsible for repeat expansions, and gene-editing strategies remain experimental, with concerns about specificity, delivery, and long-term safety. Moreover, the complexity of the DNA structures involved and the redundancy of DNA repair mechanisms make it difficult to design interventions that are both effective and selective. As a result, patients face progressive disease with limited options for modifying disease progression, underscoring the urgent need for novel solutions that can intervene at the molecular level to prevent or mitigate repeat expansions.

Technology

This technology centers on a new class of small-molecule inhibitors specifically designed to target the MSH3/MutSβ complex, a critical component of the DNA repair machinery implicated in the pathological expansion of nucleotide repeats. The compounds are built on a fused heterocyclic ring system containing sulfur and nitrogen atoms, such as triazolo[4,3-a]pyrimidine scaffolds, and are further functionalized with a variety of aryl, heteroaryl, alkyl, or amine substituents. These molecules are formulated into pharmaceutical compositions suitable for multiple administration routes—including oral, intravenous, and intracerebroventricular delivery—enabling both systemic and localized treatment. The primary therapeutic aim is to prevent or reduce the abnormal expansion of short tandem repeats, which underlies a range of severe genetic disorders like Huntington’s disease, ALS, and Friedreich ataxia, as well as certain cancers.

What differentiates this solution is its highly targeted mechanism of action and chemical versatility. By selectively inhibiting the MSH3/MutSβ pathway, these compounds address the root cause of repeat expansion at the molecular level, rather than merely alleviating symptoms. The modular chemical design allows for extensive customization of the core scaffold and substituents, optimizing pharmacological properties and specificity for diverse disease contexts. The technology is further distinguished by its broad applicability, covering a wide spectrum of repeat expansion disorders and cancers, and by its comprehensive pharmaceutical development strategy, which includes advanced formulations and multiple delivery options. Experimental validation in cell-based assays demonstrates dose-dependent activity, underscoring the therapeutic potential and translational readiness of these compounds.

Benefits

• Targets and inhibits the MSH3/MutSβ complex to modulate DNA repair and prevent abnormal nucleotide repeat expansions.
• Potentially treats a broad range of nucleotide repeat expansion disorders, including Huntington’s disease, ALS, Friedreich ataxia, fragile X syndrome, and myotonic dystrophy.
• Offers therapeutic applications for various cancers linked to nucleotide repeat instability.
• Utilizes chemically diverse small molecules with a fused heterocyclic ring scaffold, allowing for tailored specificity and potency.
• Supports multiple administration routes (oral, intravenous, intracerebroventricular, topical, etc.) for systemic or localized treatment.
• Formulated into various pharmaceutical compositions, including controlled-release and injectable forms, enhancing treatment flexibility.
• Demonstrated dose-dependent activity in cell-based assays, validating functional inhibition of the target pathway.

Applications

• Treatment of Huntington’s disease
• Treatment of ALS
• Treatment of Friedreich ataxia
• Treatment of nucleotide repeat cancers

Additional info

These small-molecule inhibitors target the MSH3/MutSβ complex to modulate DNA repair, preventing abnormal nucleotide repeat expansions. The chemical structure utilizes a fused heterocyclic scaffold, specifically triazolo[4,3-a]pyrimidine containing sulfur and nitrogen, functionalized with aryl, heteroaryl, or amine groups. These compounds treat repeat expansion disorders like Huntington’s and ALS, plus various cancers. Formulations enable oral, intravenous, or intracerebroventricular administration for systemic or localized therapeutic delivery.